UBS Global Biopharma Conference 2026
Logotype for Immunocore Holdings plc

Immunocore (IMCR) UBS Global Biopharma Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Immunocore Holdings plc

UBS Global Biopharma Conference 2026 summary

17 Nov, 2026

KIMMTRAK commercial outlook

  • KIMMTRAK is standard of care across major markets, with 70%+ penetration; growth is moderating as the product matures.

  • U.S. growth focus: deeper community-setting penetration and patient access; OUS growth mainly from new launches, patient access, and longer treatment duration in newer markets.

  • Duration of therapy is ~14 months in major markets launched for 4–5 years, versus ~10–11 months in clinical studies; U.S. duration has mostly stabilized.

Uveal melanoma combination and competition

  • Phase 1/2 study enrolled patients with unresectable or metastatic HLA-A*02:01-positive mUM; brenetafusp monotherapy enrolled 22 patients and combination with tebentafusp enrolled 26; data cutoff was June 2026.

  • In the 1L combination cohort (n=17), ORR was 29%, DCR 71%, median DOR 24.1 months and PFS 8.1 months; median OS was not reached, with 70% 2-year OS at 29 months’ median follow-up.

  • Monotherapy evaluable patients (n=16; 2L+) had 19% ORR, 63% DCR, median DOR 14.5 months, PFS 4.2 months and OS 20.3 months; 23% had prior tebentafusp.

  • TRAEs occurred in 100% of both cohorts; grade 3/4 TRAEs occurred in 45% with monotherapy and 38% with combination. No TRAE led to discontinuation or death; no new combination safety signals were reported.

  • Dual gp100/PRAME targeting aims to increase tumor engagement and T-cell killing; combination data compared favorably with historical tebentafusp monotherapy datasets in a cross-trial comparison. Randomized evaluation was in planning.

TEBE-AM in advanced cutaneous melanoma

  • Phase III TEBE-AM tests KIMMTRAK plus pembrolizumab in refractory advanced cutaneous melanoma; rationale includes GP100 expression of 85%+ in uveal and cutaneous tumors and activity of both agents.

  • Enrollment completed in the prior quarter; OS-driven results are expected in Q2 2027. Management advised against reading into the timing shift because the study is blinded.

  • Eligible patients must have failed ipilimumab/nivolumab and, if BRAF-mutant eligible, BRAF therapy; control allows locally available treatment, including retreatment, chemotherapy, palliative care or trials.

  • Expected control-arm OS is ~10–11 months based on real-world treatment mix; management said a statistically significant OS benefit would support commercial prospects.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Immunocore